Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Patent
1993-10-22
1998-03-03
Fitzgerald, David L.
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
435 6952, A61K 3820
Patent
active
057231176
ABSTRACT:
A drug for preventing and curing liver diseases comprising at least one member selected from interleukin-1 and its derivatives as an effective component. The drug meaningfully suppresses GOT and GPT activities in blood which are markers of liver diseases, and also suppresses symptoms such as choloplania.
REFERENCES:
patent: 5008374 (1991-04-01), Nakai et al.
patent: 5017692 (1991-05-01), Zurawski et al.
patent: 5120534 (1992-06-01), Hirai et al.
Muller, C. et al. (1989) Arch. Dis. Childhood 64: 205-210.
Roh, M. S., et al. (1986) Metabolism 35: 419-24.
Schilsky. M. L. et al. (1994) Am. J. Physiol. G907-G913.
Lillquist, J.S., et al. (1988) J. Immunol. 141: 1975-81.
Kamogashira, T., et al. (1988) J. Biochem. (Tokyo) 104: 837-40.
Zucali, J.R., et al. (1990) Exp. Hematol. 18: 1078-82.
Rosenwasser, L. J., et al. (1986) Proc. Natl. Acad. Sci. USA 83: 5243-46.
De Chiara, T.M., et al. (1986) Proc. Natl. Acad. Sci. USA 83: 8303-07.
Messing et al, Gene, 19:269-276 (1982).
Gluzman, Cell, 23:175-182 (1981).
Urlaub et al, Proc. Nat'l Acad. Sci USA, 77:4216-4220 (1980).
Subramani et al, Mol. Cell. Biol., 1(9):854-864 (1981).
Fumio, Taisha, 22:289-298 (1985).
Biochemistry Data Book II, K.k. Tokyo Kagaku Dojin, publisher, pp. 1175-1259 (1980).
Oppenheim et al, J. Immunol., 116:1466-1472 (1976).
Kamogashira et al, Biochem. Biophys. Res. Comm., 150:1106-1114 (1988).
Maniatis et al, Molecular Cloning, Cold Spring Harbor Laboratory, p. 366 (1982).
Sakamoto et al, Hepato-gastroenterol., 31:248-253 (1984).
McClain et al, Life Sci., 39:1479-1485 (1986).
Anastassakos et al, Clin. Exp. Immunol., 68:15-22 (1987).
Kakumu et al., J. Clin. Lab. Immunol., 26:113-119 (1988).
Anastassakos et al, Gastroenterol., 94:999-1005 (1988).
Keller et al, FEMS Microbiol. Immunol., 47:87-96 (1988).
Abe et al, Naika Mook, 34:1-12 (1987).
Mori et al, Kan.Tan.Sui (Japan), 19(5):905-910 (1989).
Kamata, General Clinics, 139(7):1837-1842 (1990).
Hoofnagle et al, Gastroenterol., 95:1318-1325 (1988).
Garcia et al, Ann. Intern. Med., 107:278-285 (1987).
Alexander et al, J. Med. Virol., 21:81-87 (1987).
Kakumu et al, Hepatology, 8:487-492 (1988).
Blum et al, Lancet, pp. 1153-1155 (Dec. 3, 1977).
Fattovich et al, Gastroenterol., 91:692-696 (1986).
Hoofnagle et al, Ann. Intern. Med., 104:12-17 (1986).
Porres et al, J. Hepatol., 8:351-357 (1989).
Auron et al, Proc. Nat'l Acad. Sci., 81:7907-7911 (1984).
March et al, Nature, 315:641-647 (1985).
Furutani et al, Nucl. Acid Res., 13(16): 5869-5882 (1985).
Hunkapiller et al, Nature, 310:105-111 (1984).
Mark et al, Proc. Nat'l Acad. Sci., 81:5662-5666 (1984).
Maxam et al, Meth. Enzym., 65:499-560 (1980).
Miyanohara et al, Proc. Nat'l Acad. Sci USA, 80:1-5 (1983).
Daniels et al, J. Hepatol., 9(1):s23 (1989).
Ozeki et al, Int. J. Exp. Path., 71:815-821 (1990).
Tovey et al, Autoimmunity, 10:297-310 (1991).
Daniels et al, Spontaneous Production of Tumor Nucrosis Factor .alpha. and Interleukin-1.beta. During Interferon-.alpha. Treatment of Chronic HBV Infection, The Lancet, 355:875-877 (1990).
Grantham et al, Nucl. Acid Res., 9:43-74 (1981).
Akamatsu Seiji
Hirai Yoshikatu
Kamogashira Takashi
Masui Yoshihiro
Nakai Satoru
Fitzgerald David L.
Otsuka Pharmaceutical Co. Ltd.
LandOfFree
Use of interleukin-1 (IL-1) to inhibit development of hepatitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of interleukin-1 (IL-1) to inhibit development of hepatitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of interleukin-1 (IL-1) to inhibit development of hepatitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2245486